leadf
logo-loader
viewRedx Pharma PLC

Redx Pharma plc - Share Option Scheme

RNS Number : 4986R
Redx Pharma plc
30 June 2020
 

Redx Pharma plc

("Redx" or "the Company")

 

New All Employee Share Option Scheme and Grant of Options

 

Alderley Park, 30 June 2020 Redx Pharma (AIM:REDX), the drug discovery and development company focused on cancer and fibrosis, announces the adoption of the Redx All Employee Share Option Scheme (the "Scheme"), effective as of 1 July 2020.   

 

Following recent announcements regarding the ownership and funding of the Company, Redx is pursuing a revised business plan and, as such, is introducing the Scheme to ensure that all employees are aligned with that business plan and the success of the Company and its shareholders.

 

The number of options that may be awarded under the Scheme, and all prior share incentive plans,  is limited such that the total of ordinary shares of 1p each under option will be less than 15 per cent. of the total issued share capital. The exercise of options awarded under the Scheme will be subject to certain time and performance criteria having been met. The options are being granted at 15.5p per ordinary share, being the price of the offer for the Company by Redmile in April 2020.

 

The Board has approved the terms of the Scheme and authorised the award of options to the following Directors and PDMR on 1 July 2020:

 

Name

Position

Number of Options

Vesting Date

Total Options following the grant

Lisa Anson (Director)

Chief Executive Officer

1,000,000

1,000,000

1,000,000

5,300,000

1 July 2021

1 July 2022

1 July 2023

1 July 2023 (subject to performance conditions)

8,300,000

James Mead (Director)

Chief Financial Officer

333,333

333,333

333,334

750,000

1 July 2021

1 July 2022

1 July 2023

1 July 2023 (subject to performance conditions)

1,750,000

Richard Armer

(PDMR)

Chief Scientific Officer

250,000

250,000

250,000

3,500,000

1 July 2021

1 July 2022

1 July 2023

1 July 2023 (subject to performance conditions)

4,250,000

 

In addition, options over 7,140,000 ordinary shares of 1p each will be granted on 1 July to the current management and staff of the company on similar terms to those above.

 

As part of the introduction of the Scheme, options held by current employees, including the directors and PDMR listed above, under the existing Enterprise Management Incentive ("EMI") scheme will be surrendered. 

 

Following the initiation of the Scheme and the grants referred to above, the Company will have granted options over a total of 21,440,000 Ordinary Shares representing 11.3 per cent. of the current total issued share capital.  In addition, certain ex-employees will continue to hold shares under the EMI scheme, totalling 2,340,800 shares representing 1.2 per cent. of the current issued share capital.

 

 

For further information, please contact:




Redx Pharma Plc 

T: +44 1625 469 918

Iain Ross, Chairman

Lisa Anson, Chief Executive




SPARK Advisory Partners (Nominated Adviser)

 T: +44 203 368 3550

Matt Davis/Henry Todd




WG Partners LLP (Broker)

T: +44 20 3705 9330

Claes Spång/Chris Lee/David Wilson






FTI Consulting

T: +44 20 3727 1000

Simon Conway/Ciara Martin


 

 


 

About Redx Pharma Plc

 

Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

 

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

 Name

Lisa Anson

2.

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Redx Pharma Plc

b)

LEI

213800HMS4EBXO589Y37

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Options over Ordinary Shares of 1p each

b)

Identification code

ISIN: GB00BSNB6S51

c)

Nature of the transactions

Grant of options under the Redx All Employee Share Option Scheme

d)

Price(s) and volume(s)

Price: 15.5p pence per share

Volume: 8,300,000 shares

e)

Aggregated information

-     Aggregated volume

-     Price

As for d) above

f)

Date of the transactions

1 July 2020

f)

Place of the transactions

Off-market

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

 Name

James Mead

2.

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Redx Pharma Plc

b)

LEI

213800HMS4EBXO589Y37

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Options over Ordinary Shares of 1p each

b)

Identification code

ISIN: GB00BSNB6S51

c)

Nature of the transactions

Grant of options under the Redx All Employee Share Option Scheme

d)

Price(s) and volume(s)

Price: 15.5p pence per share

Volume: 1,750,000 shares

e)

Aggregated information

-     Aggregated volume

-     Price

As for d) above

f)

Date of the transactions

1 July 2020

f)

Place of the transactions

Off-market

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

 Name

Richard Armer

2.

Reason for the notification

a)

Position/status

Chief Scientific Officer

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Redx Pharma Plc

b)

LEI

213800HMS4EBXO589Y37

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Options over Ordinary Shares of 1p each

b)

Identification code

ISIN: GB00BSNB6S51

c)

Nature of the transactions

Grant of options under the Redx All Employee Share Option Scheme

d)

Price(s) and volume(s)

Price: 15.5p pence per share

Volume: 4,250,000 shares

e)

Aggregated information

-     Aggregated volume

-     Price

As for d) above

f)

Date of the transactions

1 July 2020

f)

Place of the transactions

Off-market

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHQBLBXBQLZBBF

Quick facts: Redx Pharma PLC

Price: 70

Market: AIM
Market Cap: £136.67 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Redx Pharma PLC in a great place to move forward after Astra deal says CEO

Lisa Anson, chief executive of Redx Pharma PLC (LON:REDX) says the out-license deal with AstraZeneca for its fibrosis porcupine inhibitor is good news for the company and also for people suffering from the condition. Using a porcupine inhibitor in lung-scarring diseases such as IPF is a novel...

on 4/8/20

9 min read